Revance Therapeutics (RVNC) Tops Q3 EPS by 20c

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.81), $0.20 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $90 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c